Brief: Adial Pharmaceuticals - As Of Aug 10, Anticipates Termination Of CEO Cary Claiborne After 2026 Annual Meeting
13/08/2026 22:35
BRIEF-Adial Pharmaceuticals - As Of Aug 10, Anticipates Termination Of CEO Cary Claiborne After 2026 Annual Meeting Aug 13 (Reuters) - Adial Pharmaceuticals Inc ADIL.O:
ADIAL PHARMACEUTICALS - AS OF AUG 10, ANTICIPATES TERMINATION OF CEO CARY CLAIBORNE AFTER 2026 ANNUAL MEETING - SEC FILING
ADIAL PHARMACEUTICALS - ANTICIPATES MATTHEW DAVIDSON TO BE APPOINTED PRESIDENT AND CEO OF ADIAL PHARMACEUTICALS - SEC FILING
ADIAL PHARMACEUTICALS - ANTICIPATES TERMINATION OF CFO VINAY SHAH AFTER 2026 ANNUAL MEETING - SEC FILING
ADIAL PHARMACEUTICALS - ANTICIPATES BOARD CHANGES AND LEGACY MEMBER RESIGNATIONS AFTER STOCKHOLDER APPROVAL - SEC FILING
Further company coverage: ADIL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adial Pharmaceuticals
See all newsBrief: Adial Pharmaceuticals Announces Name Change To Azora Therapeutics
Brief: Adial Pharmaceuticals Announces Planned Appointment Of Celia Economides As Chief Financial Officer
Brief: Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Adial Pharmaceuticals - Proposed Resale Of Up To 25,148,970 Shares Of Common Stock By Selling Stockholders - SEC Filing
Brief: Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)